Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

155.88 -1.81 (-1.15%)
Streaming Delayed Price Updated: 10:17 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
US Stock Futures Slip As Investors Brace Themselves For Netflix, AmEx Earnings This Week — Nikkei Up On Strong Sentiment
After two days of back-to-back gains in the spot market, U.S. stock futures had a choppy session Monday night as investors await several prominent companies' earnings reports this week. 
Via Benzinga
34-Year-Old Making $3,400 a Month in Dividends Shares His Top 7 Stocks — 'Be Lucky and Save Relentlessly'
Via Benzinga
Johnson & Johnson (JNJ) Reports Earnings Tomorrow: What To Expect
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) will be reporting results tomorrow before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Examining the Future: Johnson & Johnson's Earnings Outlook
Via Benzinga
Are Tariff Worries Affecting The Earnings Outlook?
There are valid reasons for the market to remain focused on the tariffs issue since so much is happening in the broader economy. 
Via Talk Markets
Topics Stocks / Equities World Trade
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties
Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs. 
Via Benzinga
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
2 Top Dividend Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence Government Lawsuit
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study
Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety. 
Via Benzinga
Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
If Your Portfolio Is Down on the Tariff News, Check Out This Little-Known High-Yield Dividend Stock
Investors are dumping growth stocks right now as new tariff policies rock the markets. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income
Via The Motley Fool
Topics Bonds
The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now
Three of the Dow's 30 components make for sensational buys amid a historic sell-off. 
Via The Motley Fool
Topics Credit Cards Economy Stocks
This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine
Goldman Sachs upgraded Johnson & Johnson (JNJ) from Neutral to Buy, citing underappreciated Innovative Medicine business and upcoming product cycles. 
Via Benzinga
Tesla Underdelivers
And we take a look at Texas Instruments and Taiwan Semiconductor. 
Via The Motley Fool
Topics Government World Trade
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Amazon.com To $255? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
As Trump Tariffs Spark Panic, Investors Rush Into These 5 'Recession-Proof' ETFs
ETFs that provide exposure to sectors that have historically been considered defensive during downturns are now in the limelight. 
Via Benzinga
Topics ETFs Government
Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients
Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized myasthenia gravis. 
Via Benzinga
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
From Johnson & Johnson
Via Business Wire
Why Health Care Select Sector SPDR Fund (XLV) Is Moving
Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major... 
Via Benzinga
Topics Government
All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now?
Via The Motley Fool
Topics Economy Government World Trade
Amid Market Chaos, Don't Do This
Markets are under some duress, but the action should not cause you to change your thesis. While markets are facing headwinds, it’s important to realize that stocks are under duress in what feels like a... 
Via Talk Markets
Topics Stocks / Equities
President Trump's Tariffs Have Arrived. 3 Things to Do to Protect Your Portfolio.
Via The Motley Fool
Topics Economy Government Stocks
Sit Out Market Drama With These 3 Dividend Funds
Via Benzinga
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients with no new safety concerns. 
Via Benzinga
Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More
President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some notable exemptions to the steep levies. Here's a look at which products and sectors are... 
Via Benzinga
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.